Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany

Jona T. Stahmeyer; Svenja Schauer; Siegbert Rossol; Hans Heinrich Wedemeyer; Daniel Wirth; Florence Bianic; Christian Krauth

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

JHEOR

Articles
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers

search
X (formerly Twitter) (opens in a new tab)
Bluesky (opens in a new tab)
LinkedIn (opens in a new tab)
RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:6165/feed

ISSN 2327-2236

Nephrologic/Hepatologic Conditions

Vol. 1, Issue 3, 2014

December 18, 2013 EDT

Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany

Jona T. Stahmeyer, Svenja Schauer, Siegbert Rossol, Hans Heinrich Wedemeyer, Daniel Wirth, Florence Bianic, Christian Krauth,

germanymarkov modeltriple-therapycost-effectiveness analysishepatitis c

ccby-4.0

JHEOR

Stahmeyer JT, Schauer S, Rossol S, et al. Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany. JHEOR. 2013;1(3):239-253.

View more stats